Belite Bio Inc ADR BLTE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio to Participate in Four Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $155.94
- Day Range
- $149.78–170.89
- 52-Week Range
- $105.88–200.00
- Bid/Ask
- $172.80 / $175.00
- Shares Outstanding
- 40.27M
- Market Cap
- $6.84B
- Volume/Avg
- 496,545 / 181,701
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 41
- Website
- https://www.belitebio.com
Valuation
Metric | BLTE |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.87 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | BLTE |
|---|---|
Quick Ratio | — |
Current Ratio | — |
Interest Coverage | — |
Quick Ratio
BLTE
Profitability
Metric | BLTE |
|---|---|
Return on Assets (Normalized) | −18.14% |
Return on Equity (Normalized) | −18.50% |
Return on Invested Capital (Normalized) | −18.49% |
Return on Assets
BLTE
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|V%&$RtR | LOCK|q<kl& | $138B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|&pF^NF< | LOCK|$@zlk | $98B | |||
| Moderna Inc MRNA | LOCK|v?^#GTy | LOCK|xVB | $94B | |||
| argenx SE ADR ARGX | LOCK|C>g?f# | LOCK|@Z | $62B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|@zTzRP | LOCK|%N | $50B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Dt?$P>Yf | LOCK|!?@@c | $31B | |||
| Incyte Corp INCY | LOCK|^ZS&p&R | LOCK|q@% | $25B | |||
| BioNTech SE ADR BNTX | LOCK|NWKZFkD | LOCK|@&M | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|!W#&v& | LOCK|@KwZ? | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&rf?Dmx | LOCK|M# | $15B |
United States